The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Vepacel prepandemic influenza vaccine (H5N1) (whole virion, inactivated,prepared in cell culture) | Ology Bioservices Ireland LTD | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2012-02-17 | Order → |
| Zelboraf vemurafenib | Roche Registration GmbH | Melanoma | 🇪🇺 EU 2012-02-17 | Order → |
| Caprelsa vandetanib | Esteve Pharmaceuticals, S.A. | Thyroid Neoplasms | 🇪🇺 EU 2012-02-16 | Order → |
| Colobreathe colistimethate sodium | Essential Pharma Limited | Cystic Fibrosis | 🇪🇺 EU 2012-02-13 | Order → |
| Docetaxel Mylan docetaxel Generic | Mylan S.A.S. | Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Breast Neoplasms | 🇪🇺 EU 2012-01-31 | Order → |
| Desloratadine Actavis desloratadine Generic | Actavis Group PTC ehf | Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal | 🇪🇺 EU 2012-01-13 | Order → |
| Desloratadine ratiopharm desloratadine Generic | Ratiopharm GmbH | Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal | 🇪🇺 EU 2012-01-13 | Order → |
| Efavirenz Teva efavirenz Generic | Teva B.V. | HIV Infections | 🇪🇺 EU 2012-01-09 | Order → |
| Repaglinide Accord repaglinide Generic | Accord Healthcare S.L.U. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2011-12-22 | Order → |
| Topotecan Eagle topotecan Generic | Eagle Laboratories Ltd. | Carcinoma; Small Cell Lung Carcinoma | 🇪🇺 EU 2011-12-22 | Order → |
| Levetiracetam Sun levetiracetam Generic | Sun Pharmaceutical Industries Europe B.V. | Epilepsy | 🇪🇺 EU 2011-12-14 | Order → |
| Ameluz 5-aminolevulinic acid hydrochloride | Biofrontera Bioscience GmbH | Keratosis, Actinic; Carcinoma, Basal Cell | 🇪🇺 EU 2011-12-13 | Order → |
| Edarbi azilsartan medoxomil | Takeda Pharma A/S | Hypertension | 🇪🇺 EU 2011-12-07 | Order → |
| Ipreziv azilsartan medoxomil Additional monitoring | Takeda Pharma A/S | Hypertension | 🇪🇺 EU 2011-12-07 | Order → |
| Dificlir fidaxomicin | Tillotts Pharma GmbH | Clostridium Infections | 🇪🇺 EU 2011-12-05 | Order → |
| Levetiracetam Actavis Group levetiracetam Generic | Actavis Group PTC ehf | Epilepsy | 🇪🇺 EU 2011-12-04 | Order → |
| Dasselta desloratadine Generic | KRKA tovarna zdravil d.d. Novo mesto | Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Urticaria | 🇪🇺 EU 2011-11-28 | Order → |
| Edurant rilpivirine | HIV Infections | 🇪🇺 EU 2011-11-28 | Order → | |
| Eviplera emtricitabine;rilpivirine;tenofovir disoproxil | Gilead Sciences International Ltd | HIV Infections | 🇪🇺 EU 2011-11-27 | Order → |
| Desloratadine Teva desloratadine Generic | Teva B.V | Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal | 🇪🇺 EU 2011-11-24 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.